HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $591
فيرتكس للأدوية +0.96% Pre
Vertex Pharmaceuticals Incorporated VRTX | 444.28 444.28 | +0.96% 0.00% Pre |
HC Wainwright & Co. analyst Andrew S. Fein maintains Vertex Pharmaceuticals (NASDAQ:
VRTX) with a Buy and raises the price target from $518 to $591.
